This is with a mind to augmenting the actions of endogenous anti-tumor CD8+ T cells despite challenges of tumor antigenic clonal variation within a highly dynamic antigen landscape and a limited lifespan for newly generated CTLs (before exhaustion) (8, 90). This evidence concerns the gene CD8A and neoplasm.